Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Most claims are about trial demographics/age ranges and trial-specific adverse-event comparisons, which are not supported by the provided label excerpts. The only label-supported item among the list is the indication for relapsed/refractory DLBCL and the lack of age-based dosing adjustments is not addressed in the provided excerpts; therefore overall alignment is poor.
Category Scores
Accurate Statements
POLIVY was approved for relapsed or refractory DLBCL.
Section 1.2: “POLIVY in combination with bendamustine and a rituximab product is indicated for… adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.”
Unsupported Statements
POLIVY (polatuzumab vedotin-piiq) was studied in key trials including GO29365 (Phase 1b/2) and a GO29365 Phase 2 ROMULUS extension.
The provided excerpts mention “Study GO29365” in Section 14.2 but do not provide details confirming Phase 1b/2, ROMULUS, or an extension for GO29365.
Across these POLIVY studies (GO29365 Phase 1b/2 and GO29365 Phase 2 ROMULUS extension), patients ranged from 18 to 90 years old.
No age-range values for GO29365/ROMULUS are included in the provided label excerpts.
In the pivotal GO29365 trial (n=80), median patient age was 67 years.
No sample size (n=80) or median age for GO29365 is provided in the excerpts.
In the pivotal GO29365 trial (n=80), the patient age range was 29 to 86 years.
No age-range values for GO29365 are provided in the excerpts.
In the pivotal GO29365 trial, 73% of patients were 65 or older.
No proportions by age group for GO29365 are provided in the excerpts.
In the pivotal GO29365 trial, 27% of patients were under 65.
No proportions by age group for GO29365 are provided in the excerpts.
In the ROMULUS part of GO29365, median patient age was around 68 years.
No ROMULUS-specific median age value is provided in the excerpts.
In the ROMULUS part of GO29365, the patient age range extended up to 90 years.
No ROMULUS-specific maximum age value is provided in the excerpts.
POLIVY trials enrolled patients up to age 90.
The provided excerpts do not state the maximum enrolled age across trials.
There was no upper age cutoff that excluded fit elderly patients in the trials described.
The provided excerpts do not describe trial eligibility/exclusion criteria by age.
The Phase 3 POLARIX trial (n=880) reported a median age of 68 years and an age range of 18 to 80+.
The provided excerpts reference POLARIX in Section 14.1 but do not provide n=880, median age, or age range.
In the Phase 3 POLARIX trial, 43% of patients were aged 65 to 74.
No age-group proportions for POLARIX are provided in the excerpts.
In the Phase 3 POLARIX trial, 23% of patients were aged 75+.
No age-group proportions for POLARIX are provided in the excerpts.
Older patients (≥65) in these trials had higher rates of serious adverse events than younger patients (90% vs 71%).
The provided excerpts do not provide serious adverse event rates by age.
Older patients (≥65) experienced higher rates of cytopenias than younger patients.
The provided excerpts do not provide cytopenia rates by age.
Efficacy of POLIVY was consistent across ages.
The provided excerpts do not include efficacy-by-age conclusions.
Dosing adjustments for POLIVY are not age-based.
The provided dosing excerpt (Section 2.1) does not mention age-based adjustments; the label excerpts do not support a statement about whether dosing adjustments are age-based.
Monitoring increases for frailty in older patients.
The provided warnings/precautions excerpt does not mention frailty-based monitoring.
Contradictions
Low
AI Statement
POLIVY was approved for relapsed or refractory DLBCL (without qualifying “after at least two prior therapies” or specifying combination components).
Label Reference
Section 1.2 requires “in combination with bendamustine and a rituximab product” and “after at least two prior therapies.”
Important Omissions
For the indication claim, the label excerpt specifies POLIVY must be used “in combination with bendamustine and a rituximab product” and “after at least two prior therapies.”
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims assert safety/efficacy differences (serious adverse event and cytopenia rates by age) and monitoring adjustments, but these are not supported by the provided label excerpts. An imprecise indication statement omits required combination/line-of-therapy criteria.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most trial-demographics and age-stratified safety/efficacy claims are not supported by the provided label excerpts; dosing/monitoring statements are also not supported.
Suggested Improvement
Limit claims to label-supported content in the provided excerpts (e.g., Section 1.2 indication wording, Section 2.1 dosing schedule, Sections 5.x warnings, and Section 8.x population statements). Remove or re-phrase trial age and age-based safety/monitoring assertions unless the exact label text providing those numbers is provided.